IMBRUVICA^® (Ibrutinib) Plus VENCLEXTA^®/VENCLYXTO^® (Venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase III GLOW Study

AbbVie, Inc. announced new data from the Phase III GLOW study comparing the efficacy and safety of the combination of IMBRUVICA® plus VENCLEXTA®/VENCLYXTO® versus chlorambucil plus obinutuzumab for first-line treatment in patients with CLL or small lymphocytic lymphoma who had active disease requiring treatment per the International Workshop on CLL criteria.